Nervous investors miss out on Japan's biggest stockmarket rise in 26 years
British investors pulled £145m from Japanese funds in September. But they are missing out – Japan’s Nikkei 225 index gained 15% in November, its best monthly showing since 1994.

Japanese prime minister Yoshihide Suga has announced a new ¥73.6trn (£532bn) stimulus package, the country’s third so far this year. About ¥40trn (£289bn) will go towards furlough programmes, hospitals and incentives for green investment. The stimulus takes the total spent on the country’s virus to 14% of GDP.
Japan has so far dodged the worst of the pandemic, but the latest wave is its most serious, says William Pesek for the Asia Times. Japan has a serious “pre-existing condition” – about 30% of the population are aged over 65 and that proportion is rising. The debt-to-GDP ratio is more than 230% and is climbing towards 250%. “Massive national debt, a plunging population, and now, a resurgent pandemic… talk about a grim convergence.”
Upside in view
The “outlook for Japan is actually not looking too bad”, writes Robert Carnell for ING Think. More women participating in the workforce and longer careers have mitigated the “worst fears” about an ageing population. The government has been forced to step in with extra fiscal support because the Bank of Japan has run out of firepower; the central bank now owns “more than 50%” of all government debt. Its $433bn share portfolio also makes it the country’s biggest stockmarket investor. ING expects GDP to contract 5.4% for 2020 as a whole and for the economy to regain its pre-crisis level in late 2022.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Japan’s Nikkei 225 index gained 15% in November, its best monthly showing since 1994. But it remains about one-third short of its 1989 all-time peak. The Topix, which is a more accurate (if less famous) gauge of the stockmarket, is up by 3.5% so far this year.
British investors pulled £145m from Japanese funds in September, according to Investment Association data, says Jayna Rana for the Daily Mail. The wobble may have been induced by Shinzo Abe’s resignation as prime minister. They are missing out. A pro-shareholder culture is slowly taking hold thanks to Abe’s reforms, while Suga is now pushing digitalisation in a country still attached to fax machines.
The Nikkei 225 index has outperformed the US market in dollar terms this year, but few international investors have noticed, writes Mike Bird in The Wall Street Journal. Overseas buyers cooled on Abe in mid-2015 and have withdrawn funds again this year. Yet 2021 is expected to be a good year for cyclical stocks, such as industrials and consumer discretionary, which comprise “almost 40% of the MSCI Japan” index. Japanese firms also have less leverage than their overseas counterparts, which gives them a strong cash buffer for dividends – Japan yields 2.3%. When global investors cotton on, the market could soar.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.
Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.
He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.
Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.
-
‘I installed a heat pump in my home – here are five things I’ve learnt’
From the size and noise of a heat pump to how much it costs to run one, Ruth Emery reveals what she’s learnt after installing one in her home six months ago
-
3 ways to work out if a stock is good value
The only thing you can really control in investing is the price you pay for an asset – but how can you tell if you’re getting a good deal when it comes to the price of a stock?
-
Two ways to tap into monopoly profits from airports
Most investors can’t get their hands on airports. Here are two ways you can
-
Fat profits: should you invest in weight-loss drugs?
The latest weight-loss treatments could transform public health and the world economy. Should you invest?
-
How investors could profit from Ramsden Holdings' four-part growth strategy
Ramsdens Holdings offers a diversified set of financial and retail services and a juicy yield, says Dr Michael Tubbs
-
How to invest in the booming insurance market
The insurance sector is experiencing rapid growth after years of stagnation. Smart investors should buy in now, says Rupert Hargreaves
-
Out of America's shadow: Why Trump's tariff chaos may be good for non-US stocks
Opinion Upending global investment and trade could benefit other countries at the expense of the US market, says Cris Sholto Heaton
-
BP's 'long, painful decline' – and why next year could be even tougher
Opinion Long-suffering shareholders in oil giant BP have been pushing for change. It won’t come soon enough, says Matthew Lynn
-
Investment trusts tap the profits in exotic and obscure global markets
Opinion Peter Walls, manager of the Unicorn Mastertrust fund, highlights three investment trusts as he shares where he'd put his money
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.